Filing Flows

Filing Flows › Companies › Xilio Therapeutics › Cash flow

Xilio Therapeutics cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$18.8M in Q2 2026 · −$61.3M over twelve months

Operating cash flow−$18.8M
Capital spending−$19K
Free cash flow−$18.8M

Analysis

In Q2 2026, Xilio Therapeutics generated −$18.8M of operating cash flow and spent $19K on capital projects, leaving free cash flow of −$18.8M. That is $3.9M less than in Q2 2025 (−$14.9M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$60.6M; the largest uses were operating cash flow ($60.6M), capital spending ($670K); besides operations, cash came from other financing ($75.8M), shares issued ($2K); the cash balance rose by $14.5M.

Operating cash flow was −$18.8M against net income of −$6.4M. The largest differences: deferred revenue −$12.7M, receivables −$6.0M, stock-based pay +$1.6M.

Free cash flow

Xilio Therapeutics: free cash flow by quarterXilio Therapeutics: free cash flow by quarter−$13.7MQ3 2024−$14.2MQ4 2024$29.0MQ1 2025−$14.9MQ2 2025−$17.5MQ3 2025−$2.1MQ4 2025−$22.9MQ1 2026−$18.8MQ2 2026
Operating cash flow less capital spending.
Xilio Therapeutics: operating cash flow against capital spendingXilio Therapeutics: operating cash flow against capital spendingOperating cash flowCapital spending−$13.7M$9KQ3 2024−$14.2M$6KQ4 2024$29.0M$22KQ1 2025−$14.5M$401KQ2 2025−$17.5M$0Q3 2025−$2.0M$95KQ4 2025−$22.3M$556KQ1 2026−$18.8M$19KQ2 2026
Latest (Q2 2026): Operating cash flow −$18.8M, Capital spending $19K.

Capital allocation, year by year

Xilio Therapeutics: where the cash came from (up) and went (down), by fiscal yearXilio Therapeutics: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$80.8MFY2021: Net borrowing −$110KFY2021: Shares issued $262MFY2021: Capital spending −$1.1M$262MFY2021FY2022: Operating cash flow −$75.7MFY2022: Net borrowing −$85KFY2022: Shares issued $16KFY2022: Capital spending −$1.9M$16KFY2022FY2023: Operating cash flow −$68.6MFY2023: Net borrowing −$6.8MFY2023: Shares issued $8KFY2023: Capital spending −$486K$8KFY2023FY2024: Operating cash flow −$18.4MFY2024: Net borrowing −$3.4MFY2024: Shares issued $5KFY2024: Capital spending −$36K$5KFY2024FY2025: Operating cash flow −$5.0MFY2025: Shares issued $10KFY2025: Capital spending −$518K$10KFY2025
Over these 5 years operating cash flow totalled −$248M; the largest uses were operating cash flow ($248M) and net borrowing ($10.3M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$136M
Debtnone
Net cash$136M
Cash runway2.2 years

Xilio Therapeutics is burning cash: its operations consume cash, a free cash flow of −$61.3M a year at the current rate against $136M of cash and investments: a runway of about 2.2 years before any new financing.

Where the cash came from and went

Xilio Therapeutics: sources (+) and uses (−) of cash, Q2 2026Xilio Therapeutics: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$18.8MCash drawn (+) / kept (−)$14.3MOther financing$4.5MCapital spending−$19K
Xilio Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Xilio Therapeutics: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$75.8MOperating cash flow−$60.6MCash drawn (+) / kept (−)−$14.5MCapital spending−$670KShares issued$2K

From profit to cash

Xilio Therapeutics: net income to operating cash flow, Q2 2026Xilio Therapeutics: net income to operating cash flow, Q2 2026Net income−$6.4MDepreciation & amortization$331KStock-based pay$1.6MReceivables−$6.0MPayables$1.3MAccrued liabilities−$1.5MDeferred revenue−$12.7MPrepaid and other assets$624KOperating cash flow−$18.8M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$18.8M−$19K——$14.3M−$18.8M
Q1 2026−$22.3M−$556K—$1K−$12.8M−$22.9M
Q4 2025−$2.0M−$95K—$1K−$33.8M−$2.1M
Q3 2025−$17.5M———$17.8M−$17.5M
Q2 2025−$14.5M−$401K—$4K−$32.5M−$14.9M
Q1 2025$29.0M−$22K—$5K−$33.8M$29.0M
Q4 2024−$14.2M−$6K——$6.0M−$14.2M
Q3 2024−$13.7M−$9K−$7K$4K$13.7M−$13.7M

Xilio Therapeutics: income statement and cash flow

Xilio Therapeutics, Q2 2026: revenue $18.7M (+131% year over year), operating margin -18.7%. The chart follows the revenue to costs, profit and cash.

Xilio Therapeutics: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.